Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.

Patel MV, Davies H, Williams AO, Bromilow T, Baker H, Mealing S, Holmes H, Anderson N, Ahmed O.

DOI: 10.1080/13696998.2023.2248840
Published: 2023-01-01
Container: J Med Econ
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/13696998.2023.2248840,
  title = {Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.},
  author = {Patel MV and  Davies H and  Williams AO and  Bromilow T and  Baker H and  Mealing S and  Holmes H and  Anderson N and  Ahmed O.},
  year = {2023},
  journal = {J Med Econ},
  doi = {10.1080/13696998.2023.2248840},
  url = {https://doi.org/10.1080/13696998.2023.2248840}
}

RIS

TY  - JOUR
TI  - Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
AU  - Patel MV
AU  -  Davies H
AU  -  Williams AO
AU  -  Bromilow T
AU  -  Baker H
AU  -  Mealing S
AU  -  Holmes H
AU  -  Anderson N
AU  -  Ahmed O.
PY  - 2023
JO  - J Med Econ
DO  - 10.1080/13696998.2023.2248840
UR  - https://doi.org/10.1080/13696998.2023.2248840
ER  -

APA

MV, P., H, D., AO, W., T, B., H, B., S, M., H, H., N, A., & O., A. (2023). Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.. J Med Econ. https://doi.org/10.1080/13696998.2023.2248840

Source records

europe-pmc · retrieved 2026-09-26T08:19:34.725Z